What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Her main research concerns Internal medicine, Surgery, Oncology, Cancer and Carcinoma.
Her work on Internal medicine is being expanded to include thematically relevant topics such as Gastroenterology.
In the field of Surgery, her study on Radiation therapy, Larynx, Survival rate and Performance status overlaps with subjects such as Response Evaluation Criteria in Solid Tumors.
Her Oncology study combines topics from a wide range of disciplines, such as Pembrolizumab, Cetuximab, Head and neck squamous-cell carcinoma, Head and neck cancer and Nivolumab.
Lisa Licitra has included themes like Stage, Survival analysis, Pharynx and Disease in her Cancer study.
Her research integrates issues of Viral disease, Virus and Human papillomavirus in her study of Carcinoma.
Her most cited work include:
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck (1979 citations)
- Cabozantinib in Progressive Medullary Thyroid Cancer (644 citations)
- High-Risk Human Papillomavirus Affects Prognosis in Patients With Surgically Treated Oropharyngeal Squamous Cell Carcinoma (547 citations)
What are the main themes of her work throughout her whole career to date?
Lisa Licitra spends much of her time researching Internal medicine, Oncology, Head and neck cancer, Cancer and Chemotherapy.
As a member of one scientific family, Lisa Licitra mostly works in the field of Internal medicine, focusing on Surgery and, on occasion, Gastroenterology.
In her research on the topic of Oncology, Basal cell is strongly related with Head and neck.
Her Head and neck cancer research is multidisciplinary, relying on both Mucositis, Physical therapy, Randomized controlled trial and Quality of life.
Her studies in Cancer integrate themes in fields like Carcinoma, Incidence, Disease and Pathology.
Her Head and neck squamous-cell carcinoma research is multidisciplinary, incorporating perspectives in Pembrolizumab, Methotrexate, Afatinib and Hazard ratio.
She most often published in these fields:
- Internal medicine (60.36%)
- Oncology (50.27%)
- Head and neck cancer (22.16%)
What were the highlights of her more recent work (between 2018-2021)?
- Internal medicine (60.36%)
- Oncology (50.27%)
- Head and neck cancer (22.16%)
In recent papers she was focusing on the following fields of study:
Lisa Licitra focuses on Internal medicine, Oncology, Head and neck cancer, Head and neck squamous-cell carcinoma and Chemotherapy.
Her is doing research in Cetuximab, Clinical endpoint, Phases of clinical research, Adverse effect and Cancer, both of which are found in Internal medicine.
Her Oncology research integrates issues from Pembrolizumab, Immunotherapy, Clinical trial and Lenvatinib.
Her Head and neck cancer study integrates concerns from other disciplines, such as Context, Physical therapy, Quality of life and Randomized controlled trial.
Her study in Head and neck squamous-cell carcinoma is interdisciplinary in nature, drawing from both Distant metastasis, Tremelimumab, First line and Hazard ratio.
As part of one scientific family, Lisa Licitra deals mainly with the area of Chemotherapy, narrowing it down to issues related to the Radiation therapy, and often Stage, Concomitant, Performance status and Salivary duct carcinoma.
Between 2018 and 2021, her most popular works were:
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study (409 citations)
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study (380 citations)
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) (115 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
